Rachel Bhatt

Rachel Bhatt has been a leader in translating the discovery of mismatch repair deficiency as a biomarker for immunotherapy response into clinical practice. Her research characterized the high tumor mutational burden and neoantigen load in Lynch syndrome-associated and sporadic dMMR colorectal cancers. She has conducted clinical trials demonstrating remarkable checkpoint inhibitor response rates in dMMR/MSI-H colorectal cancer. Her work contributed to the first histology-agnostic FDA approval of pembrolizumab for MSI-H solid tumors.